GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (NAS:CLDX) » Definitions » Cyclically Adjusted PS Ratio

Celldex Therapeutics (Celldex Therapeutics) Cyclically Adjusted PS Ratio : 51.13 (As of Apr. 28, 2024)


View and export this data going back to 1990. Start your Free Trial

What is Celldex Therapeutics Cyclically Adjusted PS Ratio?

As of today (2024-04-28), Celldex Therapeutics's current share price is $36.30. Celldex Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $0.71. Celldex Therapeutics's Cyclically Adjusted PS Ratio for today is 51.13.

The historical rank and industry rank for Celldex Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

CLDX' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.39   Med: 18.58   Max: 73.07
Current: 51.06

During the past years, Celldex Therapeutics's highest Cyclically Adjusted PS Ratio was 73.07. The lowest was 0.39. And the median was 18.58.

CLDX's Cyclically Adjusted PS Ratio is ranked worse than
92.67% of 505 companies
in the Biotechnology industry
Industry Median: 5.24 vs CLDX: 51.06

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Celldex Therapeutics's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.079. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.71 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Celldex Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Celldex Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celldex Therapeutics Cyclically Adjusted PS Ratio Chart

Celldex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.57 12.43 35.91 57.40 55.79

Celldex Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.40 49.41 46.21 38.21 55.79

Competitive Comparison of Celldex Therapeutics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Celldex Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celldex Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's Cyclically Adjusted PS Ratio falls into.



Celldex Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Celldex Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=36.30/0.71
=51.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celldex Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Celldex Therapeutics's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.079/129.4194*129.4194
=0.079

Current CPI (Dec. 2023) = 129.4194.

Celldex Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.070 99.695 0.091
201406 0.099 100.560 0.127
201409 0.185 100.428 0.238
201412 0.247 99.070 0.323
201503 0.079 99.621 0.103
201506 0.332 100.684 0.427
201509 0.156 100.392 0.201
201512 0.272 99.792 0.353
201603 0.198 100.470 0.255
201606 0.211 101.688 0.269
201609 0.331 101.861 0.421
201612 0.260 101.863 0.330
201703 0.188 102.862 0.237
201706 0.459 103.349 0.575
201709 0.454 104.136 0.564
201712 0.379 104.011 0.472
201803 0.434 105.290 0.533
201806 0.281 106.317 0.342
201809 0.086 106.507 0.105
201812 0.152 105.998 0.186
201903 0.116 107.251 0.140
201906 0.051 108.070 0.061
201909 0.036 108.329 0.043
201912 0.054 108.420 0.064
202003 0.157 108.902 0.187
202006 0.011 108.767 0.013
202009 0.017 109.815 0.020
202012 0.095 109.897 0.112
202103 0.017 111.754 0.020
202106 0.088 114.631 0.099
202109 0.003 115.734 0.003
202112 0.007 117.630 0.008
202203 0.004 121.301 0.004
202206 0.003 125.017 0.003
202209 0.009 125.227 0.009
202212 0.034 125.222 0.035
202303 0.020 127.348 0.020
202306 0.006 128.729 0.006
202309 0.032 129.860 0.032
202312 0.079 129.419 0.079

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Celldex Therapeutics  (NAS:CLDX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Celldex Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Celldex Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Celldex Therapeutics (Celldex Therapeutics) Business Description

Traded in Other Exchanges
Address
53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
Executives
Garry Arthur Neil director 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Tibor Keler officer: Sen. VP & Ch Scientific Off. 30 PARK ROAD, OTTSVILLE PA 18942
Sarah Cavanaugh officer: SVP of Corp. Affairs & Admin. C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Diane C. Young officer: SVP, Chief Medical Officer 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
Anthony S Marucci director, officer: President and CEO 66 COLD HILL DRIVE, MENDAHM NJ 07945
Richard M. Wright officer: Sr. VP & CCO C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Samuel Bates Martin officer: SVP and CFO C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Margo Heath-chiozzi officer: SVP of of Regulatory Affairs C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Elizabeth Crowley officer: SVP, Chief Product Dev Officer C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Freddy A. Jimenez officer: SVP & General Counsel C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
James J Marino director C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Keith L Brownlie director 777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Gerald Phd Mcmahon director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114